Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma.
Ontology highlight
ABSTRACT: Cisplatin is the first-line chemotherapeutic agent for the treatment of oral squamous cell carcinoma (OSCC). However, the intrinsic or acquired resistance against cisplatin remains a major obstacle to treatment efficacy in OSCC. Recently, mitochondrial DNA (mtDNA) alterations have been reported in a variety of cancers. However, the role of mtDNA alterations in OSCC has not been comprehensively studied. In this study, we evaluated the correlation between mtDNA alterations (mtDNA content, point mutations, large-scale deletions, and methylation status) and cisplatin sensitivity using two OSCC cell lines, namely SAS and H103, and stem cell-like tumour spheres derived from SAS. By microarray analysis, we found that the tumour spheres profited from aberrant lipid and glucose metabolism and becam
SUBMITTER: Aminuddin A
PROVIDER: S-EPMC7217862 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
ACCESS DATA